Planning Committee
Raquel D. Arias, MD Penelope M. Bosarge, RNC, MSN, CRNP David A. Grimes, MD Andrew M. Kaunitz, MD Anne A. Moore, MSN, ANP, FAANP |
Susan Rawlins, MS, RNC, WHNP Suzy L. Reiter, NP, MSN Lee P. Shulman, MD Carolyn M. Sutton, MS, WHNP Susan Wysocki, RNC, NP |
Planning Committee and Faculty DisclosuresDr Arias has indicated relevant financial relationships as noted: retained consultant for Barr Laboratories, Inc., Berlex, Inc., Organon Pharmaceuticals USA, Inc., Pfizer Inc, Novo Nordisk, and Wyeth Pharmaceuticals. Ms Bosarge has indicated relevant financial relationships as noted: speakers bureau and consultant for Duramed Pharmaceuticals, Inc., Ortho-McNeil Pharmaceuticals, Inc., and Wyeth Pharmaceuticals, Inc. Dr Grimes has indicated relevant financial relationships as noted: speakers bureau for Berlex, Inc. and Duramed Pharmaceuticals, Inc. Dr Kaunitz has indicated relevant financial relationships or affiliations as noted: grant/research support from Berlex, Inc., Duramed Pharmaceuticals, Inc., and Organon Pharmaceuticals USA, Inc.; speaker and/or consultant for Berlex, Inc., CooperSurgical, Inc., Duramed Pharmaceuticals, Inc., Johnson & Johnson, Organon Pharmaceuticals USA, Inc., Pfizer Inc., and Warner Chilcott; stockholder in Procter and Gamble, Noven Pharmaceuticals, Inc., sanofi-aventis, Barr, and Johnson & Johnson. Ms Moore has indicated relevant financial relationships as noted: retained consultant and speaker for Berlex, Inc., Duramed Pharmaceuticals, Inc., Organon Pharmaceuticals USA Inc., Ortho-McNeil Pharmaceutical, Inc., and Wyeth Pharmaceuticals. Ms Rawlins has indicated relevant financial relationships as noted: retained consultant for Duramed Pharmaceuticals, Inc. and Ortho Women’s Health; speaker for Ortho Women’s Health. Ms Reiter has indicated relevant financial relationships as noted: advisor for Berlex Inc., Merck & Co., Inc., and Ortho-McNeil, Inc.; speaker for Merck & Co., Inc. and Organon. Dr Shulman has indicated relevant financial relationships as noted: consultant for Berlex, Inc., Ortho-McNeil, Inc., Wyeth-Ayerst Pharmaceuticals, Pfizer Inc., F. Hoffmann-LaRoche Ltd., and Eli Lilly and Company; receives research grants or contracts from Wyeth-Ayerst Pharmaceuticals and Duramed Pharmaceuticals, Inc. Ms Sutton has indicated relevant financial relationships as noted: speakers bureau for Berlex, Inc., Ortho-McNeil Pharmaceutical, Inc., Pfizer Inc, and Wyeth Pharmaceuticals. Ms Wysocki has indicated relevant financial relationships as noted: grant/research support from Berlex, Inc., Wyeth Pharmaceuticals, Inc., Ortho-McNeil, Inc., Organon USA, Inc., Eli Lilly and Company, Duramed Pharmaceuticals, Inc., Novogen, Esprit Pharma, Inc., Merck & Co. and Digene, Inc., and speaker and advisory board member for Digene, Berlex, Inc., Wyeth Pharmaceuticals, Inc., Ortho-McNeil, Inc., Organon USA, Inc., and Duramed Pharmaceuticals, Inc.; website contributor for Novogen. |
|
